TY - JOUR
T1 - IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
AU - Cerchione, Claudio
AU - Romano, Alessandra
AU - Daver, Naval
AU - DiNardo, Courtney
AU - Jabbour, Elias Joseph
AU - Konopleva, Marina
AU - Ravandi-Kashani, Farhad
AU - Kadia, Tapan
AU - Martelli, Maria Paola
AU - Isidori, Alessandro
AU - Martinelli, Giovanni
AU - Kantarjian, Hagop
N1 - Publisher Copyright:
© Copyright © 2021 Cerchione, Romano, Daver, DiNardo, Jabbour, Konopleva, Ravandi-Kashani, Kadia, Martelli, Isidori, Martinelli and Kantarjian.
PY - 2021/3/29
Y1 - 2021/3/29
N2 - Recently, the discovery of biological and clinical properties of mutated isoforms 1 and 2 mutations of isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with acute myeloid leukemia (AML), lead to the development of an individualized treatment strategy. Promoting differentiation and maturation of the malignant clone targeting IDH is an emerging strategy to promote clinical responses in AML. Phase I/II trials have shown evidence of safety, tolerability, and encouraging evidence of efficacy of two small molecule inhibitors targeting IDH2 and IDH1 gene mutations, respectively enasidenib and ivosidenib. In this review, the contribution of IDH1/IDH2 mutations in leukemogenesis and progress of targeted therapeutics in AML will be highlighted.
AB - Recently, the discovery of biological and clinical properties of mutated isoforms 1 and 2 mutations of isocitrate dehydrogenases (IDH) 1 and 2, affecting approximately 20% of patients with acute myeloid leukemia (AML), lead to the development of an individualized treatment strategy. Promoting differentiation and maturation of the malignant clone targeting IDH is an emerging strategy to promote clinical responses in AML. Phase I/II trials have shown evidence of safety, tolerability, and encouraging evidence of efficacy of two small molecule inhibitors targeting IDH2 and IDH1 gene mutations, respectively enasidenib and ivosidenib. In this review, the contribution of IDH1/IDH2 mutations in leukemogenesis and progress of targeted therapeutics in AML will be highlighted.
KW - AML
KW - IDH
KW - acute myeloid leukemia
KW - enasidenib
KW - isocitrate dehydrogenase
KW - ivosidenib
KW - target therapy
UR - http://www.scopus.com/inward/record.url?scp=85105008222&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105008222&partnerID=8YFLogxK
U2 - 10.3389/fonc.2021.639387
DO - 10.3389/fonc.2021.639387
M3 - Review article
C2 - 33898313
AN - SCOPUS:85105008222
SN - 2234-943X
VL - 11
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 639387
ER -